It is made available under a CC-BY-ND 4.0 International license .

- 1 Protection conferred by Delta and BA.1/BA.2 infection against BA.4/BA.5 infection and
- 2 hospitalization: A Retrospective Cohort Study
- 3 Nicole E Winchester, BS¹, Nabin K. Shrestha, MD², Priscilla Kim, BA, MS¹, Larisa G.
- 4 Tereshchenko, MD, PhD³, Michael B Rothberg, MD, MPH³
- ⁵ ¹Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland,
- 6 Ohio, USA
- 7 ²Department of Infectious Disease, Cleveland Clinic, Cleveland, Ohio, USA
- ³Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA
- 9 ⁴Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio, USA
- 10
- 11 Author Contributions and Conflicts of Interest: We have no conflicts of interest to disclose. All
- 12 authors have seen and approved the manuscript, and have contributed significantly to the work.
- 13 The statistical analyses were conducted by NEW and LGT. No funding was received to assist
- 14 with the preparation of this manuscript
- 15
- 16 Abstract
- 17 Background: SARS-CoV-2 immunity has declined with subsequent waves and accrual of viral

18 mutations. In vitro studies raise concern for immune escape by BA.4/BA.5, and a study in Qatar

- 19 showed moderate protection, but these findings have yet to be reproduced.
- 20 Methods: This retrospective cohort study included individuals tested for COVID-19 by PCR
- 21 during Delta or BA.1/BA.2 and retested during BA.4/BA.5. The preventable fraction (PF) was
- 22 calculated as ratio of the infection/hospitalization rate for initially positive patients divided by
- 23 infection/hospitalization rate for initially negative patients, stratified by age, and adjusted for
- age, gender, comorbidities, and vaccination using logistic regression.
- 25 **Results:** 20,987 patients met inclusion criteria. Prior Delta infection provided no protection
- against BA.4/BA.5 infection (Adjusted PF: 11.9% (95% confidence interval [CI], 0.8-21.8);
- p=0.036) and minimal protection against hospitalization (Adjusted PF: 10.7% (95%CI, 4.9-21.7);
- p=0.003). In adjusted models, prior BA.1/BA.2 infection provided 45.9% (95%Cl, 36.2-54.1) (p
- 29 <0.001) protection against BA.4/BA.5 reinfection and 18.8% (95% CI, 10.3-28.3) (p<0.0001)
- 30 protection against hospitalization. Up-to-date vaccination provided modest protection against
- reinfection with BA.4/BA.5 and hospitalization.
- 32 **Conclusions:** Prior infection with BA.1/BA.2 and up-to-date vaccination provided modest
- protection against infection with BA.4/BA.5 and hospitalization, while prior Delta infection
- 34 provided minimal protection against hospitalization, and no infection protection.

It is made available under a CC-BY-ND 4.0 International license .

36 Introduction

37	Since the emergence of SARS-CoV-2 in 2019, multiple new strains have emerged, challenging
38	the protection afforded by natural immunity, vaccination, and neutralizing antibody
39	treatments. In the United States, these variants have included B.1.1.7 (Alpha), B.1.351 (Beta),
40	B.1.1.28.1 (Gamma) and B.1.617.2 (Delta) [1], and most recently Omicron [1]. Prior to the
41	emergence of Omicron, previous infection appeared to provide 80-90% protection against
42	reinfection [2-9]. However, infection with pre-Omicron variants only provided 18-69%
43	protection against reinfection with Omicron [10-11]. Since then, additional spike protein
44	mutations have accrued, enabling progressive immune escape by new Omicron sub lineages
45	[12-14].
46	By June 25 th , two new Omicron subvariants, BA.4 and BA.5, became dominant in the United
47	States [1]. In vitro studies raise concern that their additional spike protein mutations may
48	enable immune evasion and repeat Omicron infections. Antibodies generated against the spike
49	protein by BA.1 infection are evaded by BA.4/BA.5 [12], and neutralizing antibody titers
50	following triple vaccination [13] or previous infection with BA.1 or BA.2 are substantially lower
51	[13]. However, these studies have been limited to <i>in vitro</i> analysis of humoral immunity. A
52	recent study in Qatar showed that infection with pre-Omicron variants was 28% effective at
53	protecting against BA.4/BA.5 infection, while infection with early Omicron variants was 76%
54	effective [15]. However, these findings have yet to be reproduced or evaluated in other
55	populations, including the US, where patients are substantially older [15]. Moreover, this study
56	did not assess the impact of prior infection or vaccination on hospitalization. Clinical data are

It is made available under a CC-BY-ND 4.0 International license .

57 needed to define such protection in order to guide guarantine and isolation guidelines and

- 58 future vaccine development.
- 59 As the pandemic has progressed, the public health priority has shifted from preventing all
- 60 infections to reducing disease spread and disease severity, especially hospital admissions. We
- 61 therefore designed our study to address two specific aims: 1) to determine the degree to which
- 62 infection with Delta or Omicron subvariants BA.1/BA.2 and up-to-date vaccination protects
- against reinfection with BA.4/BA.5 and 2) to determine the preventable fraction of BA.4/BA.5
- 64 hospitalizations attributable to prior infection with Delta or BA.1/BA.2 and up-to-date
- 65 vaccination.

66 <u>Methods</u>

- 67 Study Design
- 68 We conducted a retrospective cohort study of patients within the Cleveland Clinic health69 system.
- 70 Study Populations and SARS-CoV-2 Exposures
- 71 The study population included individuals aged 18 years or older tested for COVID-19 via
- polymerase chain reaction (PCR) between July 1, 2021 and August 18, 2022. To assess the
- 73 protection afforded by Delta and early Omicron (BA.1/BA.2) infection against BA.4/BA.5, the
- 74 data were divided into two cohorts according to the CDC reported variant proportions. Patients
- tested between July 1, 2021 and December 25, 2021 were included in the Delta cohort. Patients
- tested between December 26, 2021 and June 24, 2021 were included in the BA.1/BA.2 cohort.

77	Only patients tested during Delta and/or BA.1/BA.2 and then retested during the period of
78	BA.4/BA.5 predominance (June 25, 2022 to August 18, 2022) were included. Patients with a
79	positive COVID test before July 1, 2021 or during both the Delta and BA.1/BA.2 waves were
80	excluded. In addition, because the CDC defines reinfection as occurring \geq 90 days after initial
81	testing, patients with a positive test within 90 days of BA.4/BA.5 testing were also excluded.
82	Patients with PCR testing during Delta and BA.1/BA.2 were included in both analyses if they
83	only tested positive during one wave, or neither. The reasons for PCR testing included
84	symptoms consistent with
85	COVID-19, hospital admission for any indication, pre-procedural screening, and travel
86	clearance.
87	
88	COVID vaccination status at the time of BA.4/BA.5 predominance was confirmed by review of
89	the EMR. Patients were classified as up-to-date if they had completed a two-dose series
90	(Moderna or Pfizer) or a single dose vaccine (Johnson & Johnson's Janssen or Astra Zeneca
91	vaccine) and then received an additional vaccine dose within six months prior to June 25, 2022.
92	Data Collection
93	Data were extracted from the electronic medical record. Variables collected included age, sex,
94	BMI, ICD-9 codes for hypertension, diabetes mellitus, chronic kidney disease, heart failure, and
95	stroke as well as COVID vaccine dose type and date(s), COVID PCR test date(s) and indications,
96	hospitalization, ICU admission, and mechanical ventilation.

97 Statistical Analysis

It is made available under a CC-BY-ND 4.0 International license .

Infection rates were calculated as the number of positive tests divided by the total number of
subjects retested. For aim 1, the fraction of BA.4/BA.5 infections that could have been
prevented (preventable fraction (PF)) by prior infection with Delta or BA.1/BA.2 was calculated
as 1 minus the ratio of the infection rate for initially positive patients divided by the infection
rate for initially negative patients.

$$PF_{reinfection} = 1 - Risk Ratio$$

 $= 1 - \frac{BA.4/BA.5 infection rate amongst previously infected}{BA.4/BA.5 infection rate amongst previously uninfected}$

103 To assess for differences in protection by age, we stratified the preventable fraction by age (18-

104 64 years, 65 years and up). Lastly, the adjusted PF of infection was calculated by logistic

regression, comparing the odds of having versus not having prior SARS-CoV-2 infection among

106 patients with BA.4/BA.5 infection as:

108

109 Logistic regression models were adjusted for age, sex, body mass index (BMI), and

110 comorbidities (hypertension, diabetes mellitus, chronic kidney disease, heart failure, and

stroke). Each model included an indicator variable for prior infection during Delta or BA.1/BA.2

and an indicator variable for up-to-date vaccination.

113 For the second aim, the adjusted PF was calculated for hospitalization. The fraction of

BA.4/BA.5 hospital admissions that could have been prevented (PF) by prior infection with

115 Delta or BA.1/BA.2 was calculated as:

116 Adjusted PF_{hospitalization} = 100 × (1-Adjusted Odds Ratio_{hospitalization})

It is made available under a CC-BY-ND 4.0 International license .

1	1	7
т.	т	1

118	Logistic regression models were adjusted for age, sex, BMI, comorbidities (hypertension,
119	diabetes mellitus, chronic kidney disease, heart failure, and stroke), and included an indicator
120	variable for prior infection during Delta or BA.1/BA.2 and up-to-date vaccination.
121	Analyses were conducted using R v.4.2.1 (R Core Team, Vienna) and STATA/MP 17.0 (StataCorp,
122	College Station, TX). To adjust for testing of 10 hypotheses, p-value < 0.005 was considered to
123	be statistically significant. The Cleveland Clinic Institutional Review Board approved this work.
124	<u>Results</u>
125	Between July 1, 2021 and August 18, 2022, 20,987 individuals met study inclusion criteria
126	(average age, 58.5 ± 19.2 years; 57.4% female). Characteristics of patients who received a PCR
127	test during the period of Delta, BA.1/BA.2, and BA.4/BA.5 predominance are shown in Table 1.
128	During the Delta wave, 15,658 patients were tested for SARS-CoV-2 by PCR, of whom 15.2%
129	tested positive. During the period of Omicron subvariants BA.1/BA.2 predominance, 10,545
130	patients were tested for SARS-CoV-2 by PCR, of whom 17.9% tested positive. Overall, 17.0% of
131	these individuals retested positive during BA.4/BA.5.
132	Protection against reinfection with Omicron subvariants BA.4/BA.5 by prior SARS-CoV-2
133	infection
134	In unadjusted analyses, previous infection with BA.1/BA.2 provided modest protection against
135	reinfection during the period of BA.4/BA.5 predominance with a PF of 38.0% (95% CI, 29.9-
136	43.3%). However, prior Delta infections did not provide any protection against BA.4/BA.5

reinfection in unadjusted analyses. PF of BA.4/BA.5 infections by prior Delta infection was 5.5%
(-2.8 to 13.2%).

139 Protection against reinfection stratified by age is shown in Table 2. Older adults (\geq 65 years)

140 infected during BA.1/BA.2 appeared to derive greater protection against reinfection than did

141 younger adults (<65).

142 After adjusting for age, gender, BMI, comorbidities (HTN, DM, CKD, CHF, stroke), and up-to-

143 date vaccination status, prior infection with BA.1/BA.2 still provided modest protection against

144 BA.4/BA.5 reinfection. Prior BA.1/BA.2 infection conferred 45.9% (95% Cl, 36.2-54.1)(p<0.0001)

145 protection against reinfection with BA.4/BA.5. After adjustment, prior Delta infection provided

no protection against BA.4/BA.5, 11.9% (95%CI, 0.8-21.8); p=0.036. In the Delta model, up-to-

147 date vaccination status provided significant protection against BA.4/BA.5, with a PF of 22.7%

148 (95%CI, 14.8-29.8); p<0.0001. The efficacy of up-to-date vaccination against BA.4/BA.5 in the

149 BA.1/BA.2 model was 29.8% (95%Cl, 20.5-38.1); p<0.0001.

150 **Prevention of hospitalization**

151 In the unadjusted analysis, previous infection with SARS-CoV-2 during the BA.1/BA.2 wave

offered 44.6% (95% Cl, 31.7-55.7) protection against hospitalization during the BA.4/BA.5 wave.

153 Delta infections did not confer significant protection against hospitalization during BA.4/BA.5.

154 However, after adjusting for age, gender, comorbidities, and vaccination status, prior Delta

- infection was effective at preventing 10.7% (95%Cl, 4.9-21.7)(p=0.003) of BA.4/BA.5
- hospitalizations, while BA.1/BA.2 infection prevented 18.8% (95%CI, 10.3-28.3); p<0.0001.
- 157 Efficacy of up-to-date vaccination in preventing hospitalization, after adjustment, was 20.0%

medRxiv preprint doi: https://doi.org/10.1101/2022.11.14.22282310; this version posted November 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

(95%Cl, 13.9-25.7)(p<0.0001) in the Delta model, and 22.9% (95%Cl, 15.5-29.6)(p<0.0001) in the
BA.1/BA.2 model.

160 **Discussion**

In this retrospective cohort study of 20,987 individuals tested for SARS-CoV-2, previous Delta 161 infection provided no protection against reinfection with Omicron subvariants BA.4/BA.5 and 162 minimal protection against hospitalization. However, prior infection with earlier Omicron 163 164 subvariants BA.1/BA.2 offered significant, albeit modest, protection against both reinfection 165 and hospitalization. Up-to-date vaccination provided modest protection against hospitalization 166 for both patients included in the Delta and BA.1/BA.2 analyses. Unexpectedly, we found that protection against reinfection was greater for older adults than for those under the age of 65 167 168 years.

Our study demonstrates that infection with pre-Omicron variant Delta offers no significant 169 protection against BA.4/BA.5 infection. This is consistent with *in vitro* studies showing complete 170 171 immune evasion of BA.4/BA.5 by neutralizing antibodies induced by prior infections or 172 vaccination. Clinical studies have shown a progressive decline in protection conferred by prior SARS-CoV-2 infection against newer variants. While SARS-CoV-2 infection provided 80-90% 173 protection against reinfection with pre-Omicron variants [2-9], studies of the initial Omicron 174 variant found that past infection, at least with Delta, offered some protection, but not at the 175 176 levels seen with earlier variants [10,16]. A recent study in Qatar found that pre-Omicron 177 infections were 27.7% (95% CI, 19.3 to 35.2) effective at preventing BA.4/BA.5 infections [15]. It 178 is important to note that they matched cases and controls by the week of their COVID test,

It is made available under a CC-BY-ND 4.0 International license .

179	which could better adjust for potential waning in natural immunity over time. However, we
180	have previously shown that waning does not occur for at least 12 months [4,6]. Additionally,
181	their study included individuals who received antigen testing and adjusted for testing
182	indication. Their population was generally young and asymptomatic, and they therefore did not
183	report on hospitalizations. Our cohort included an older, less healthy population, who received
184	PCR testing in a healthcare setting rather than home antigen testing. Our cohort may therefore
185	represent a population at higher risk of SARS-CoV-2 reinfection or adverse outcomes. Together,
186	their findings and ours highlight a dramatic decline in the efficacy of natural immunity against
187	newer SARS-CoV-2 variants, which may be most profound for our vulnerable populations.
188	Surprisingly, we found that following infection with BA.1/BA.2, older adults derived greater
189	protection against BA.4/BA.5 than did younger adults. Prior studies have shown that natural
190	immunity against COVID declines with advancing age. These unexpected findings, also seen
191	with BA.1 [10], may be explained by differences in social behavior. It is plausible that following
192	infection with COVID, older adults perceive their vulnerability and take greater precautions to
193	avoid reinfection. Conversely, younger adults may feel they are protected against reinfection
194	and no longer worry about catching it. Therefore they take fewer precautions, putting them at
195	higher risk of exposure and infection. However, no differences were seen between younger and
196	older adults with prior Delta infections. This suggests that the results were not completely a
197	behavioral artifact. One explanation is that infection is dose dependent. Behaviors of older
198	patients may have reduced the size of the inoculum and because the patients infected with
199	BA.1/BA.2 had some immunity, they avoided infection, whereas older patients who had been

It is made available under a CC-BY-ND 4.0 International license .

- infected with Delta were susceptible even to a very small exposure. Alternatively, the impact of
 infection on behavior may have been short-lived.
- Prior infection with BA.1/BA.2, and to a minimal degree, Delta, also offered significant
- 203 protection against hospitalization. Rates of ICU admission and mechanical ventilation were
- remarkably low during BA.4/BA.5, at only 4.0 and 0.9%, respectively, making it impossible to
- assess the impact of prior infection on these more serious outcomes.
- Lastly, these findings are a sobering reminder of the challenges in preventing the spread of
- 207 COVID-19, and the need for ongoing vaccine development. Our findings suggest that natural
- 208 immunity is insufficient to prevent reinfections with immunologically different variants. While
- in vitro studies suggested that vaccination may be ineffective against BA.4/BA.5 [17], we found
- 210 that up-to-date vaccination was modestly effective at preventing BA.4/BA.5 reinfection and
- 211 hospitalization, even for patients without prior exposure to Omicron. These findings provide
- some reassurance and emphasize the importance of recent vaccination. Ongoing development
- 213 of variant specific vaccines is needed to further improve their protective effect.
- The strengths of this study include its large sample size, validity of PCR-confirmed SARS-CoV-2 infection, and adjustment for vaccine status, age, and common comorbidities. Inclusion of these demographic and clinical characteristics allowed us to explore the separate roles of natural immunity and vaccination in preventing SARS-CoV-2 reinfections, as well as their interactions.
- 219 While we were able to adjust for certain demographic variables and comorbidities, this study 220 has several important limitations. Due to the rapid uptake of home antigen testing following

It is made available under a CC-BY-ND 4.0 International license .

221	the Delta wave, there may have been unmeasured differences between patients who
222	presented for testing in the clinical setting versus testing at home. Additionally, greater time
223	elapsed between Delta infections and BA.4/BA.5 exposure, than for BA.1/BA.2 infections.
224	Several studies have shown that natural immunity persists for at least one year before waning
225	[4,6]. However, our study alone cannot exclude the possibility that the lack of protection
226	conferred by Delta infection is due to waning immunity. This study is also unable to account for
227	differences in patient behavior involving avoidance of SARS-CoV-2 exposures. While age may
228	account for some differences in behavior, we cannot further differentiate natural immunity
229	from avoidance of exposures. Still, the extent to which we found minimal impact of previous
230	infection remains concerning.
231	In conclusion, previous infection with Delta conferred no protection against reinfection with
232	BA.4/BA.5 and minimal protection against hospitalization, regardless of vaccine status or age.
233	BA.1/BA.2 infection offered limited protection against both. It seems unlikely that herd
234	immunity will be possible. Future vaccines are necessary if more severe variants begin to
235	circulate. Such vaccines will require rapid dissemination, prior to the emergence of new
236	variants, in order to be effective as a public health intervention.

It is made available under a CC-BY-ND 4.0 International license .

238	References
239	
240	1. Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US
241	Department of Health and Human Services, CDC; 2022, July 07. <u>https://covid.cdc.gov/covid-</u>
242	data-tracker.
243	2. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates Among Patients Who
244	Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. Clin
245	Infect Dis 2021;73:1882-6.
246	3. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection
247	against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in
248	2020: a population-level observational study. Lancet 2021;397:1204-12.
249	4. Kim P, Gordon SM, Sheehan MM, Rothberg MB. Duration of Severe Acute Respiratory
250	Syndrome Coronavirus 2 Natural Immunity and Protection Against the Delta Variant: A
251	Retrospective Cohort Study. Clin Infect Dis 2022;75:e185-e90.
252	5. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2
253	Infection in Health Care Workers. N Engl J Med 2021;384:533-40.
254	6. Shrestha NK, Burke PC, Nowacki AS, Terpeluk P, Gordon SM. Necessity of Coronavirus
255	Disease 2019 (COVID-19) Vaccination in Persons Who Have Already Had COVID-19. Clin Infect
256	Dis 2022;75:e662-e71.
257	7. Grant R, Charmet T, Schaeffer L, et al. Impact of SARS-CoV-2 Delta variant on incubation,
258	transmission settings and vaccine effectiveness: Results from a nationwide case-control study in
259	France. Lancet Reg Health Eur 2022;13:100278.
260	8. Leidi A, Koegler F, Dumont R, et al. Risk of Reinfection After Seroconversion to Severe
261	Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score
262	Matched Cohort Study. Clin Infect Dis 2022;74:622-9.
263	9. Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 Reinfection 1 Year After
264	Primary Infection in a Population in Lombardy, Italy. JAMA Intern Med 2021;181:1407-8.
265	10. Rothberg MB, Kim P, Shrestha NK, Kojima L, Tereshchenko LG. Protection Against the
266	Omicron Variant Offered by Previous SARS-CoV-2 Infection: A Retrospective Cohort Study. Clin
267	Infect Dis 2022.
268	11. Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron Variant
269	from Previous SARS-CoV-2 Infection. N Engl J Med 2022;386:1288-90.
270	12. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by
271	Omicron infection. Nature 2022;608:593-602.
272	13. Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron
273	Subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med 2022;387:86-8.
274	14. Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature
275	
276	15. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective Effect of Previous SARS-CoV-
277	2 Infection against Omicron BA.4 and BA.5 Subvariants. New England Journal of Medicine 2022.
278	16. Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron Variant
279	from Previous SARS-CoV-2 Infection. New England Journal of Medicine 2022;386:1288-90.
280	17. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by
281	Omicron infection. Nature 2022.

It is made available under a CC-BY-ND 4.0 International license .

It is made available under a CC-BY-ND 4.0 International license .

Characteristic	Delta		BA.1/BA.2		BA.4/BA.5	
	SARS-CoV-2(+)	SARS-CoV-2(-)	SARS-CoV-2(+)	SARS-CoV-2(-)	SARS-CoV-2(+)	SARS-CoV-2(-
n	2,380	13,278	1,886	8,659	3,558	17,429
Age <u>+</u> SD, y	52.3 <u>+</u> 19.1	58.9 <u>+</u> 19.1	55.7 <u>+</u> 19.5	60.7 <u>+</u> 18.4	56.4 <u>+</u> 19.4	59.0 <u>+</u> 19.1
Female, n (%)	1,378 (57.9)	7,785 (58.6)	1,075 (57.0)	4,781 (55.2)	2,093 (58.8)	9,956 (57.1)
HTN, n (%)	1,210 (50.8)	7,976 (60.1)	1,066 (56.5)	5,597 (64.6)	1,857 (52.2)	10,539 (60.5)
DM, n (%)	597 (25.1)	3,902 (29.4)	539 (28.6)	2,781 (32.1)	846 (23.8)	5,112 (29.3)
CHF, n (%)	361 (15.2)	2,885 (21.7)	373 (19.8)	2,183 (25.2)	505 (14.2)	3,799 (21.8)
CKD, n (%)	363 (15.3)	2,816 (21.2)	388 (20.6)	2,120 (24.5)	566 (15.9)	3,701 (21.2)
Stroke, n (%)	347 (14.6)	2,824 (21.3)	370 (20.6)	1,971 (22.8)	556 (15.6)	3,666 (21.0)
Overweight, n (%)	623 (26.2)	3,828 (28.8)	506 (26.8)	2,476 (28.6)	1,071 (30.1)	4,936 (28.3)
Obese, n (%)	1,198 (50.3)	5,453 (41.1)	838 (44.4)	3,647 (40.0)	1,505 (42.3)	7,306 (41.9)
BA.4/BA.5 +, n (%)	400 (16.8)	2,315 (17.4)	187 (9.9)	1,369 (15.8)	х	х
Up-to-date vaccination, n	622 (26.1)	4,378 (33.0)	519 (27.5)	2,978 (34.4)	922 (25.9)	5,736 (32.9)
(%)						
Unadjusted PF (95% Cl), %	5.5 (-2.8		•	9.9-43.3)	2	x
Adjusted PF (95% Cl), %, (p- value)*	11.9(0.8-21.8	3) (p=0.036)	45.9(36.2-54.	1) (p<0.0001)	2	x

Table 1. Patient characteristics and unadjusted preventable fractions (PF) for prevention of BA.4/BA.5 infection by prior SARS-CoV-2 infection status

*Adjusted for age, gender, and comorbidities. Both exposures (previous SARS-CoV-2 infection and vaccination)
 were included in the model

were included in the model.

287

288

It is made available under a CC-BY-ND 4.0 International license .

Wave	Age group (years)	BA.4/BA.5 reinfection cases, N		BA.4/BA.5 reinfection incidence proportion, %		Preventable fraction, %	Pairwise P-value
		Exposed	Unexposed	Exposed	Unexposed		
Delta	18-64	419	1,865	19.6%	19.4%	-1.1%	<0.001
	<u>></u> 65	102	1,241	11.7%	17.0%	30.9%	Ref
BA.1/BA.2	18-64	192	1,035	12.4%	17.9%	30.9%	<0.001
	>65	60	792	6.9%	15.6%	55.6%	Ref

290 Table 2. Protection against Reinfection with the Omicron subvariants BA.4/BA.5 by age group

It is made available under a CC-BY-ND 4.0 International license .

298 Table 3. BA.4/BA.5 infection outcomes by prior COVID Status and preventable fraction (PF) of

299 hospitalizations

	Delta+	Delta-	BA1BA2+	BA1BA2-	
	(n= 400)	(n= 2,315)	(n = 187)	(n=1,369)	
Hospitalization, n(%)	164 (41.1)	963 (41.6)	47 (25.1)	628 (45.9)	
ICU admission, n(%)	11 (2.8)	93 (4.0)	5 (2.7)	62 (4.5)	
Mechanical ventilation, n(%)	5 (1.3)	19 (0.8)	0	15 (1.1)	
Hospitalization, Unadjusted 1.3 PF (95% CI), %		9.9 – 12.0)	44.6 (31.7-55.7)		
Hospitalization, Adjusted PF (95%Cl), % (p-value)*	10.7% (95%Cl, 4.9-21.7) (p=0.003)		18.8% (95%CI, 10.3-28.3) (p<0.0001)		

300 *Adjusted for age, gender, and comorbidities. Both exposures (previous SARS-CoV-2 infection and vaccination)

301 were included in the model.